BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Regulatory News: OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that Ergoplex™, its commercial anti-inflammatory product using its patented compound, Ergothioneine, a powerful antioxidant, has shown very good acceptance in a recent direct mail test. Response rates ranged from 1.6% to 2.2%; levels indicative of broad consumer acceptance.
